Search Site | Index | News & Reports

About Lymphoma | Advocacy | Art | CAM | Clinical trials 
Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms |
Tests | Treatments | Types of Lymphoma | How to Help


Find Clinical Trial

 by Agent
by Type of Lymphoma & Treatment Status  

 Trials of Interest

New trials since MAY 2019

  Phase I since 2017  | Phase III since 2008
 
Guidelines at Diagnosis | About Clinical Trials

evidence-based support and information

 

PAL's picks - Clinical Trials of Interest 

By Type of Lymphoma:
 AIDS/HIV-related | ALCL | Burkitt's | CLL/SLL |  CNS Lymphoma
DLBCL |  Follicular | Hodgkin  | Mantle Cell | Marginal Zone (MALT) 
T-cell Lymphomas | Mixed types of lymphoma |  WM | GVHD ....                What's New?
Trial Talk  to find an expert in your region to help you decide if a study is a good decision based on your unique circumstance
 Find Trials for Lymphoma or CLL:  Alphabetical  | New since Jan 2016  | Phase I since 2014  | Phase III since 2014

 
Trials of interest

Last update: 06/11/2019  

 

NOTICE

Over a decade we’ve converted queries of clinicaltrials.gov into shortcut URLS. This so users of lymphomation can click once to find trials by agent or other criteria, such as lymphoma subtype. Doing this allows me to also count how many people have clicked the link.

Bitley converted the URLs to USA.gov short urls for government sites such as for clinicaltrials.gov, NASA, NOA, etc as a way to show the URL was a reliable USA.gov site.

The Trump administration ended it without, as far as I know, opportunity for public comment.
See https://blog.usa.gov/decommissioning-1-usa-gov  for the notice.

I will rebuild some of these queries of clinicaltrials.gov, starting with find trials by agent name A to Z. It will take some time.

 

WHAT'S NEW

bullet
Study of interest: The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study - Full Text View - ClinicalTrials.gov http://bit.ly/2SfxMk0 

Newly diagnosed NHL patients will be recruited from each center participating in the LEO cohort. At time of consent, participants will be asked to completed several questionnaires collecting health history, current medical and quality of life questions. Patients will also provide a baseline blood sample that will processed locally and stored centrally for future research use.
bullet
Testing Betalutin (CD37-directed radioimmunotherapy) for Rituxan/CD20-refractory follicular lymphoma - US, Europe, Canada, UK http://bit.ly/2RbGcs0 

Testing Betalutin (CD37-directed radioimmunotherapy) for Treatment of Relapsed or Refractory Diffuse Large B cell lymphoma ineligible for transplant - US, Europe, UK http://bit.ly/2G0zpiO 

Testing Betalutin (CD37-directed radioimmunotherapy) and Rituximab in Follicular Lymphoma - ClinicalTrials.gov - Oslo, Norway http://bit.ly/2MtKCKd 

About Betalutin (CD37-directed radioimmunotherapy) http://bit.ly/2WhZrUO 
Contact for Betalutin trials:
 
bullet
Phase Ib trial of an ibrutinib-based combination therapy in recurrent/refractory CNS lymphoma. - PubMed - NCBI http://bit.ly/2QR6Qey
bullet
Multi-center, accelerated titration dose study of TG-1801 (anti-CD47/anti-CD19 bispecific antibody) in B-Cell Lymphoma - ClinicalTrials.gov http://bit.ly/2R8JY5o
 
bullet
Obinutuzumab (cd20 mab) + Umbralisib (PI3K delta inhibitor),
OR Obinutuzumab + Umbralisib + Lenalidomide
OR Obinutuzumab -Chemotherapy for early (within 24 month)
Relapsed or Refractory Grade I-IIIa Follicular Lymphoma http://bit.ly/2QDhPTO 
 
bullet
A Study of Zanubrutinib (btk inhibitor - BGB-3111) Versus Ibrutinib in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia - Full Text View - ClinicalTrials.gov http://bit.ly/2Hpeet6

Zanubrutinib (BTK inhibitor) Granted Breakthrough Designation for Mantle Cell Lymphoma http://bit.ly/2FFGcOP 
bullet
Comparing Bendamustine and Rituximab (BR) Alone to BR given with  Acalabrutinib (btk-inhibitor) in Patients over 65 years of age with Previously Untreated Mantle Cell Lymphoma - ClinicalTrials.gov http://bit.ly/2OBnYUw  
bullet
Testing Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma  http://bit.ly/2ghv64V
bullet
Testing clarithromycin-lenalidomide in patients with rrMALT lymphoma in phase-II “CLEO” trial https://clinicaltrials.gov/ct2/show/NCT03031483 
bullet
Testing CD30 t-cell CAR (cellular therapy) for CD30-Expressing Lymphomas http://bit.ly/2n7LPNq
bullet
Nivolumab (immune checkpoint MAb) + Brentuximab Vedotin (cd30-drug-conj)
After SCT for High-Risk Classical Hodgkin http://bit.ly/2mY9HD2
bullet
Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma http://bit.ly/2ia1qVE
bullet
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Alliance Trials http://bit.ly/2i72jn2
 
bullet
Relapsed Indolent Lymphoma (FL, MZL ..)
Testing Lenalidomide (immune-modulator)
and GA101 (cd20 mab)  Open

New
bullet
Testing safety of TGR-1202 (PI3K-delta Inhibitor)
and Ibrutinib (btk-inhibitor)
for Relapsed and Refractory Diffuse Large B-Cell Lymphoma http://bit.ly/2bRW6po
bullet
Denintuzumab Mafodotin
(SGN-CD19A antibody-drug conjugate)
With RCHOP/RCHP VS RCHOP in DLBC or FL Lymphoma http://bit.ly/2amcOPr

Report on Phase 1 safety:  http://bit.ly/2aXcLdS
 
bullet
Targeting a validated immune-pathway target in novel way:

Testing CA-170 (small molecule, Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) for advanced cancer and Lymphomas http://1.usa.gov/28W6he3 
bullet
Testing Gene Therapy for HIV Virus-Related Lymphoma Receiving Stem Cell Transplant  http://1.usa.gov/1U4l4Pq 
bullet
Elderly (75+yrs.) With previously untreated DLBC Lymphoma
Testing Brentuximab Vedotin (antibody-drug conjugate), with Rituxan, and with Dose Attenuated CHP (CHOP minus vincristine)  http://1.usa.gov/1Stlnoc
bullet
Relapsed / refractory B-cell Lymphoma
Testing Oral Selinexor for Receiving R-DHAOx or R-GDP http://1.usa.gov/1YGTQkX
bullet
Follicular Lymphoma, previously untreated
without a current need to treat
Testing Rituximab (cd20 antibody) With or Without Zevalin (radio-labeled cd20 antibody) Open  
Clicks as of 4/6/16:  91  Today: >
bullet
Follicular lymphoma, previously untreated
Testing Intratumoral G100 (TLR4 agonist) +/- Pembrolizumab (anti-pd1 antibody - immune checkpoint inhibitor)  Open
: 17  Today: >
bullet
Find Trials for Lymphoma or CLL:  
Alphabetical  | New since Jan 2016 
Phase I since 2014  | Phase III since 2014
bullet
Adding the following queries to each:
By treatment status - to limit list of trials to your setting
Phase I trials - to see what is newest - just emerging
Open Phase III controlled trials - to see potentially practice changing studies that you might also consider
bullet
CLL -- Richter's Transformation
Testing PNT2258 (BCL-2-targeted liposomal packaging of 24-base DNA oligonucleotide )  Open
bullet
AIDS/HIV-related lymphoma studies
bullet
ALCL studies
bullet
Burkitt's studies
 



  
 

This resource is intended as an aid in the discussion of trials.

Requiring NO registration
or disclosure of personal information.

It's about advancing research, yes,
but also it's about increasing the number and types of choices
 for patients when treatment is needed.

 


AIDS / HIV-related lymphomas   

bullet
Locate trials for AIDS / HIV-related lymphoma
Open Controlled Studies Click count: >
By treatment status: Untreated  > | Relapsed  >
bullet
Testing EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection Open
bullet
HIV-Related Aggressive B-Cell Lymphomas
Testing Vorinostat and Combination Chemotherapy With Rituximab in  Open
bullet
AIDS-related Primary Brain Lymphoma
Testing Chemotherapy and HAART  Open

 

  

 
Anaplastic Large Cell (ALS) Lymphoma

bullet
Locate trials for for lymphoma
Open Phase III Controlled trials  Click count: >
Open Phase I trials  >
By treatment status: Untreated  > | Relapsed >
bullet

Comparing Brentuximab Vedotin and CHP With CHOP in CD30-positive Mature T-cell Lymphomas Open

 

  


Burkitt's Lymphoma 

bullet
Locate trials for Burkitt's lymphoma
Open Controlled Studies Click count: >
By treatment status: Untreated  > | Relapsed  >

 

  


CLL/SLL 

 See also lymphoma, mixed types

bullet
Locate trials for CLL/SLL
Open Phase III Controlled trials Click count: >
Phase I trials >
By treatment status: Untreated  > | Relapsed  >
bullet
CLL -- Richter's Transformation
Testing PNT2258 (BCL-2-targeted liposomal packaging of 24-base DNA oligonucleotide )  Open
bullet
CLL and SLL, untreated with need to treat
Comparing Ibrutinib + Rituximab to FCR (chemoimmunotherapy)  Open
bullet
Buparlisib
bullet
CLL, relapsed or refractory
Testing Lenalidomide, Rituximab and Ibrutinib  Open
bullet
CLL or Aggressive lymphoma including transformed, relapsed or refractory
Testing Selinexor  /KPT-330 and Ibrutinib  
   
bullet
CLL
Testing Idelalisib With BI 836826 (anti-cd37) in CLL
bullet
Buparlisib

Return to Top


 

CLL/SLL
From our picks that are no longer recruiting.

bullet
CLL/SLL Relapsed or Refractory with 17p Deletion
Testing: ABT-199 an inhibitor of BCL-2 
 Clicks as of 6/13/14: 123 Today: >
bullet
CLL / SLL, relapsed requiring treatment
 Expanded Access Idelalisib in Combination With Rituximab
Clicks as of 8/13/14: 56 Today: >
bullet
CLL / SLL relapsed < 36 months after last treatment with current need to treat
Comparing: Idelalisib With Bendamustine VS Rituxan VS Bendamustine and Rituxan Clicks as of 4/27/14: 88 Today: >  
bullet
CLL / SLL relapsed OR previously untreated, OR no prior transplant
 Testing: ABT-199 WITH Rituxan
Clicks as of 6/13/14: 170 Today: >
bullet

CLL/SLL Relapsed or Refractory
Comparing: Bendamustine-Rituxan (B-R) to B-R with Ibrutinib 
Clicks as of 4/27/14: 127 Today: >
bullet
CLL / SLL with current need to treat, over 65 years of age OR having 17p or p53 risk factors
Testing: Ibrutinib  
Clicks as of 10/18/13: 104 Today: >  
bullet
CLL / SLL  previously untreated, - elderly (over 65 years)
 Comparing: Lenalidomide VS Chlorambucil As First Line Therapy  (The ORIGIN Trial  Clicks as of 10/18/13: 72  Today: > 
bullet
CLL / SLL previously untreated OR relapsed, need to treat, no transformation Comparing Ibrutinib WITH FC-Rituxan VS Bendamustine-Rituxan   Clicks as of 10/18/13: 156 Today:  > 
bullet
CLL / SLL relapsed <24 months since last treatment with
current need to treat, AND not eligible for chemo
Comparing: Idelalisib (GS-1101 / CAL101) with Rituxan VS Rituxan with Placebo  Clicks as of 10/18/13: 72 Today: > 
bullet
CLL / SLL relapsed or refractory
Comparing IPI-145 Versus Ofatumumab  (DUO) 
Clicks as of 1/28/16: 64  Today: >
bullet
CLL / SLL Early-Stage Asymptomatic
 Testing Lenalidomide + Vaccine
Clicks as of 1/28/16: 62 Today: >
 

 
 CNS Lymphoma - Central Nervous System  Lymphoma

bullet
Locate trials for CNS Lymphoma
Open Phase III Controlled Studies  (fixed) >
By treatment status: Untreated  | Relapsed
bullet
CNS Lymphoma, primary
Testing: Ibrutinib and Immuno-Chemotherapy Using
Dose-Adjusted Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, Rituximab (DA-TEDDI-R) http://1.usa.gov/1hbcH8j 

Patients Summary | Trial Summary (PDF) 
: 14 Today: >
bullet
CNS Lymphoma - primary, previously untreated
 Testing: Chemo WITH or WITHOUT Autologous Stem Cell Transplant
Study drug reports  : 33 Today: >
bullet
CNS / intraocular Lymphoma relapsed or refractory 
 Testing: Lenalidomide WITH Rituxan
 Study drug reports : 61 Today: > 

Return to Top
 
 
 

CNS Lymphoma
From our picks that are no longer recruiting

(to be added)


 DLBCL (Diffuse Large B-Cell Lymphoma)

 See also Lymphoma - mixed types, aggressive

bullet
Locate trials for DLBCL
Open Phase III Controlled studies  (fixed) >
By treatment status: Untreated | Relapsed
DLBCL with c-myc genetic change
bullet
DLBCL - previously untreated
Testing Denintuzumab Mafodotin
(SGN-CD19A antibody-drug conjugate)
With RCHOP/RCHP VS RCHOP in DLBC or FL Lymphoma http://bit.ly/2amcOPr

Report on Phase 1 safety:  http://bit.ly/2aXcLdS
 
bullet
DLBCL, PMBCL type, relapsed
Testing Pembrolizumab (pd-1 immune checkpoint inhibitor)
: 16 Today: > 
bullet
DLBCL, previously untreated
Testing Pembrolizumab (pd1 antibody) with R-CHOP
: 16 Today: > 
bullet
DLBCL, newly diagnosed
Testing Rituximab and Combination Chemotherapy With or Without Lenalidomide for Newly Diagnosed Stage II-IV DLBC Lymphoma Open
 : 27 Today: > 
bullet
DLBCL, relapsed - including transformed from FL
Testing MDV9300 (anti-pd-1) in R/R Diffuse Large B-cell Lymphoma (DLBCL) including transformed
: 26 Today: > 
bullet
DLBCL, ABC subtype, relapsed
Testing ACP-196 (Btk Inhibitor) for relapsed Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma Open 
 : 88 Today: > 
bullet
DLBCL, relapsed
Testing PNT2258 (first-in-class DNAi ) for Pretreated Diffuse Large B-Cell Lymphoma (Wolverine) Open
: 34 Today: > 

ASH 2013: Paper: The BCL2 Targeted Deoxyribonucleic Acid Inhibitor (DNAi) PNT2258 Is Active In Patients With Relapsed Or Refractory Non-Hodgkin’s Lymphoma Report
Reports http://bit.ly/1B9gKGD | http://1.usa.gov/Z53YLF
bullet
DLBCL newly diagnosed, ABC subtype
 Comparing Ibrutinib + CHOP-R VS CHOP-R 
 : 27  Today: >
bullet
DLBCL relapsed or refractory
 Testing Ibrutinib + Lenalidomide, With and Without Rituxan 
 : 80  Today: >

Return to Top
 

 
 
DLBCL
From our picks that are no longer recruiting
bullet
DLBCL relapsed, not eligible for transplant or failed last transplant
Testing Nivolumab (immune checkpoint inhibition)
   : 42  Today: >
bullet
DLBCL previously untreated
Comparing Zevalin to Observation AFTER Standard R-CHOP 
 : 67  Today: > 
 (Terminated)
bullet
Lymphoma, mixed aggressive - DLBCL including transformed
relapsed or refractory AND not eligible for transplant
Testing 5-azacitidine (epigenetic agent) WITH Vorinostat (HDAC inhibitor)
 Study drug reports Clicks as of 4/27/14: 69  Today: > 
bullet
DLBCL or transformed follicular with CD79 Mutation
Testing AEB071 a Protein Kinase C Inhibitor
  Clicks as of 4/27/14: 67  Today: > 
(Terminated)

DLBCL previously untreated
Testing 5-azacitidine (epigenetic) WITH R-CHOP (standard therapy)
 Clicks as of 4/27/14: 18  Today: >
(needs verification)
bullet
DLBCL previously untreated
Testing 5-azacitidine (epigenetic) WITH R-CHOP (standard therapy)
   Clicks as of 4/27/14: 43  Today: >
bullet
DLBCL including subtypes, previously untreated
Comparing CHOP-R to EPOCH-R 
   Clicks as of 4/27/14: 152 Today:  > 
bullet

DLBCL relapsed or refractory
Testing Ibrutinib (Bruton's Tyrosine Kinase Inhibitor)
Study drug reportsClicks as of 4/27/14:  43  Today:  > 
 

 
 Follicular lymphoma

  See also lymphoma, mixed types
 

bullet
Locate trials for Follicular Lymphoma
Open Phase III Controlled studies Click count: >
Phase I studies >
By treatment status: Untreated | Relapsed
bullet
Follicular Lymphoma, previously untreated
without a current need to treat
Testing Rituximab (cd20 antibody) With or Without Zevalin (radio-labeled cd20 antibody) Open  
Clicks as of 4/6/16:  91  Today: >
bullet
Follicular, previously untreated
Testing Intratumoral G100 (TLR4 agonist) +/- Pembrolizumab (anti-pd1 - immune checkpoint inhibitor)  Open
: 17  Today: >
bullet
Follicular Lymphoma, relapsed, refractory to Rituxan
Testing IPI-145 With Rituximab vs Rituximab in Previously Treated Follicular Lymphoma - ClinicalTrials.gov Open  
 : 63  Today: >  Report 
bullet
Follicular, relapsed/refractory
Testing Nivolumab (immune checkpoint blockade) in  Lymphoma Open
 : 63  Today: >

Key eligibility:  > or = 2 prior treatment lines; each of the 2 prior treatment lines must include at least Rituximab and/or an Alkylating agent
bullet
Follicular lymphoma, untreated, without symptoms
Testing Rituximab With or Without Zevalin in Treating Patients With Untreated, Asymptomatic Follicular Lymphoma Open  
 : 61  Today: >
bullet
Follicular lymphoma, advanced stage, previously untreated
Testing Response-adapted Strategy (molecular response by MRD) following standard RCHOP
 : 26 Today: >
bullet
Follicular lymphoma, relapsed or refractory
Comparing ABT-199 + Bendamustine + Rituximab (BR) TO BR or ABT-199 + R
Study drug reports : 61 Today: >
 

Return to Top

 

  

 
bullet
Follicular lymphoma stage I or II, grade I or II
- previously untreated
Testing Radiation Therapy WITH Rituxan
 Clicks as of 7/30/15: 72 Today: >
(Status not known)
Follicular Lymphoma
From our picks that are no longer recruiting
 
bullet
Follicular lymphoma, refractory
Testing Ibrutinib as single agent
 Study drug reports  Clicks as of 7/30/15: 101 Today: >
  
bullet
Follicular Lymphoma, previously untreated
Testing Ibrutinib, Lenalidomide, and Rituxan
Clicks as of 7/30/15: 115  Today: >
bullet
Follicular lymphoma grade 1-3a, stage II-IV - previously untreated with current need to treat
Testing Lenalidomide with RITUXAN followed by Rituxan maintenance  OR
 Rituxan-based chemotherapy followed by Rituxan Maintenance
Clicks as of 7/30/15: 91 Today: >
bullet
Follicular lymphoma relapsed - responded to prior Rituxan-based treatment
Testing Idelalisib (GS-1101 / CAL101) WITH Lenalidomide AND WITH Rituxan
Clicks as of 7/30/15: 139  Today: >
bullet
Follicular lymphoma relapsed, responsive to last Rituxan
Testing: Lenalidomide, OR Rituxan, OR Rituxan WITH Lenalidomide
 Clicks as of 10/18/13: 132  Today: >
bullet Terminated: Follicular lymphoma previously untreated, measurable disease but not bulky
Testing Veltuzumab (cd20 antibody) AND Fractionated 90Y- Epratuzumab Radioimmunotherapy
 Study drug reports : 71  Today: > 

 

 
Hodgkin Lymphoma

 See also Lymphoma - mixed, aggressive, and indolent

bullet
Locate trials for Hodgkin Lymphoma
Open Phase III Controlled studies 
By treatment status: Untreated  | Relapsed
bullet
High-Risk Classical Hodgkin, relapse from SCT
Nivolumab (immune checkpoint antibody) + Brentuximab Vedotin (cd30 antibody-drug-conjugate)   Open
bullet
Hodgkin Lymphoma, relapsed or refractory
Testing Mocetinostat (HDAC inhibitor) with Brentuximab Vedotin in Patients With Relapsed or Refractory Hodgkin Lymphoma Open 
 : 22  Today: > 

mocetinostat NCI Drug dictionary - cancer.gov 
bullet
Hodgkin Lymphoma, relapsed or refractory
Testing Ipilimumab and Brentuximab Vedotin
 Study drug reports   :  74  Today:  > 
bullet
Hodgkin Lymphoma stage II-IV, previously untreated, age 60 years or older
Testing Brentuximab Vedotin AND Combination Chemotherapy (ADV)
 Study drug reports Clicks as of 10/19/13: 35 Today: >
bullet
Hodgkin Lymphoma primary refractory OR relapsed
Testing Radiolabeled Monoclonal Antibody Therapy AND Combination Chemotherapy BEFORE Stem Cell Transplant
: 51   Today: > 

Return to Top

 
 

 

Hodgkin Lymphoma
From our picks that are no longer recruiting
 
bullet
Hodgkin Lymphoma relapsed after autologous transplant OR at least 2 prior multi-agent chemotherapy regimens in patient not eligible for transplant
Testing PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin
   :  57  Today:  >
bullet
Hodgkin Lymphoma relapsed or refractory, no prior salvage therapy
Testing Brentuximab Vedotin WITH Bendamustine
   Clicks as of 10/19/13:  47  Today:  >
bullet

Hodgkin Lymphoma, relapsed or refractory
Testing PI3K Delta Inhibitor TGR-1202, Given With Brentuximab Vedotin
 Study drug reports :  57  Today:  >   
bullet

Hodgkin Lymphoma, untreated stage I/II, non-bulky
Testing ABVD chemotherapy - Intensity and Type of Chemo Based on Result of PET Scan
 :  28  Today:  > 
 


 
 Lymphoma - mixed types in same trial

 See also: DLBCL | Hodgkins | CLL / SLL | Follicular | Mantle Cell | T-cell

bullet
Locate trials for mixed types of lymphoma or CLL
All Studies 
By treatment status:
Phase III - open Controlled studies
Phase I: All types | CLL | NHL | HL
Mixed aggressive section
bullet
Lymphoma, mixed:
DLBCL & transformed, relapsed or refractory
  Testing denintuzumab mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for DLBC Lymphoma  Open 
 : 7   Today: > 
bullet
n B-cell Lymphoma
Biopsy-proven refractory after frontline chemo-immunotherapy Open  
 : 17   Today: > 

Relapsed or refractory B-cell NHL, including
Diffuse large B-cell lymphoma (DLBCL) and
DLBCL not otherwise specified (NOS)
Transformed DLBCL from indolent histology and
Follicular lymphoma Grade 3B.
 
bullet
Lymphoma, mixed b-cell types,
aggressive lymphoma, cd20-positive, relapsed
  Testing Belinostat (HDAC inhibitor) WITH Zevalin 
 Key eligibility: CD20 positive DLBCL, MCL, high grade-B-cell or anaplastic large B cell NHL;
AND bone marrow =< 20% involvement; first relapse eligible if not a candidate for transplant.

 Study drug reports  Clicks as of 4/27/14: 63 Today: >
bullet
Lymphoma, mixed
aggressive types relapsed or refractory
  Testing KPT-330 + RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma, including transformed FL Open
 : 49   Today: > 

Technical Background Report
 
bullet
Lymphoma, mixed b-cell types:
relapsed and refractory to chemotherapy
   Testing Adoptive T-cell therapy:  Genetically Engineered Lymphocyte Therapy

Study drug reports Clicks as of 4/27/14: 33 Today: > (China)
bullet
Lymphoma, mixed b-cell types:
NHL OR CLL cd-19 positive, high-risk, refractory to chemotherapy including FL, MCL, and DLBCL
    Testing  Adoptive T Cells therapy engineered to target CD19

Clicks as of 4/27/14: 49  Today: >  

 Key eligibility: CD19+ B cell lymphomas
with no available curative treatment options (such as autologous or allogeneic SCT)
Mixed Aggressive or Indolent section
bullet
Lymphoma, mixed b-cell types: - transformed from indolent
  Testing Ibrutinib
Study drug reports  Clicks as of 8/13/14: 35 Today: > 
bullet
Lymphoma, mixed b-cell types - relapsed or refractory
  Testing Ibrutinib with Lenalidomide

Study drug reports  Clicks as of 4/27/14: 107 Today: > 
bullet
Lymphoma, mixed b-cell types: low or high grade - including DLBCL, relapsed and refractory
  Testing DCDT2980S OR DCDS4501A (antibody - drug conjugates) WITH Rituxan
Study drug reports  Clicks as of 4/27/14: 59  Today: >   
bullet
: 38   Today: >   
bullet
Lymphoma, mixed b-cell types, indolent
Testing Duvelisib (IPI-145) With Rituximab (R) & Bendamustine (B) vs BR +Placebo  - Open
: 27  
bullet
Relapsed Indolent Lymphoma (FL, MZL ..)

Testing Lenalidomide (immune-modulator)
and GA101 (cd20 mab)  Open
New
bullet
Lymphoma, mixed b-cell types, relapsed
  Testing Ibrutinib Given With Nivolumab in Participants With Hematologic Malignancies - Open
 : 51 Today: >   
bullet
Lymphoma -  mixed b-cell types,  relapsed or refractory
Testing Daratumumab  (anti-cd38) in Relapsed/Refractory b-cell lymphoma - Open
: 44   Today: > 
bullet
Lymphoma -mixed b-cell types, relapsed or refractory
  Testing Lenalidomide + Rituximab THEN: Lenalidomide OR Rituxan Maintenance for Relapsed/Refractory FL, MCL, MZL Lymphoma Open
 : 49   Today: > 

Discussion:  http://bit.ly/1DGFtTU
bullet
Lymphoma, mixed types:
follicular or DLBCL, relapsed or refractory
  Testing Polatuzumab Vedotin With cd20 antibody With Bendamustine in Relapsed or Refractory Follicular DLBC Lymphoma Open
 : 59   Today: > 

* About Polatuzumab Vedotin http://bit.ly/ZXRo1t
bullet
Lymphoma, mixed types:
Indolent b-cell lymphoma,
relapsed, responded to last Rituxan therapy, no transformed
  Comparing Idelalisib + Bendamustine-Rituxan VS  Bendamustine-Rituxan
 Participants have a 2:1 chance of being assigned to Idelalisib-based treatment group
 Study drug reports : 113 Today: >
bullet
Lymphoma, mixed types:
NHL, CLL, or Hodgkins
   Testing LAG-3 antibody, safety study anti-LAG-3 monoclonal antibody BMS-986016
 Study drug reports : 39  Today: > 
bullet
Lymphoma, mixed types:
b or t-cell, Hodgkin AND NHL
relapsed, with no CNS involvement or active autoimmune disease
  Testing PD-1 - Anti-Programmed Death-1 AND Ipilimumab 
Study drug reports  Background on mechanism: PAL  
: 129  Today: > 
bullet
Lymphoma, mixed types:
with no risk of autoimmune disease, no prior transplant, or CNS involvement
   Testing PD-L1 antibody (MPDL3280A)
Background: PAL   :  63  Today:  >  
bullet
Lymphoma, mixed types:
relapsed or refractory NHL or Hodgkin lymphoma
must have at least one measureable lesion > 1.5 cm 
   Testing PD-1 (Nivolumab) and Ipilimumab (two immune-checkpoint agents)
Study drug reports : 53  Today: > 
Return to Top
 
  




 
 
Includes transformed from indolent:
bullet
Lymphoma, mixed types:
CLL or Aggressive lymphoma including transformed, relapsed or refractory
  Testing Selinexor and Ibrutinib  ial  (fixed link)
bullet
Lymphoma, mixed types:
DLBCL or transformed follicular with CD79 Mutation OR ABC subtype
  Testing AEB071 ((a Protein Kinase C Inhibitor) + EVEROLIMUS  
: 16  Today: > 
bullet
Lymphoma, mixed
aggressive b-cell types, chemo refractory
  Testing engineered t-cells (CART19 /KTE-C19) in chemo-refractory Aggressive Lymphoma (NHL) – including transformed FL - ClinicalTrials.gov Open  
 : 81   Today: > 
Related Report
bullet
Lymphoma, mixed b-cell types:
ALL, CLL, NHL, relapsed refractory, follicular, nodal Marginal Zone
  Testing Adoptive t-cell therapy: Laboratory Treated T Cells (anti-CD19-CAR autologous T cells)
Location: Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium CNS lymphoma not specified but not excluded in the Eligibility section.

Study drug reports  : 740 Today: > 
Less common mixed types
bullet
Lymphoma, EBV-Associated
  Testing Adoptive t-cell therapy - LMP1/2-Specific

Study drug reports  : 53   Today: > 
bullet
Lymphoma, mixed types: T-cell or Hodgkins lymphoma:  relapsed or refractory
  Testing CPI-613 + Bendamustine
Study drug reports  : 19  Today: > 
bullet
Lymphoma, mixed types:
B or T-cell lymphoma, relapsed or refractory
 Testing Romidepsin + Oral 5-Azacitidine (epigenetic agents) 
Study drug reports : 23  Today: > 
bullet
Lymphoma, mixed types:
Hodgkins OR NHL, second or subsequent relapsed after Stem cell Transplant
  Testing Adoptive T-cell therapy: Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes 
Study drug reports : 88 Today: > 
bullet
Lymphoma, mixed types, Hodgkin OR anaplastic large-cell  - relapsed - failed or declined transplant
  Testing Brentuximab Vedotin (antibody-drug conjugate) WITH Bendamustine 
Key eligibility:  relapsed HL or ALCL; for HL, failed or declined stem cell transplant
 Study drug reports : 113  Today:  >
bullet
B-cell lymphoma:  MCL, Low Grade NHL, SLL/CLL), Transformed, DLBCL/PMBCL,
Hodgkin's Disease - relapsed and refractory
   Testing Everolimus WITH Rituxan maintenance AFTER High-dose Consolidative Therapy
Study drug reports  : 50  Today: > 
bullet
Lymphoma, mixed types:
B-cell, including MCL and transformed - poor risk, relapsed or refractory
  Testing Zevalin WITH Rituxan-BEAM Chemotherapy, THEN Autologous Stem Cell Transplant
 : 15  Today: >  (DONE)
bullet
Lymphoma, mixed types: FL, MCL, MZL, Relapsed/Refractory
  Testing Lenalidomide + Rituximab folllowd by: Lenalidomide OR Rituxan Maintenance
Study drug reports   : 49  Today: > 

Return to Top

 

Lymphoma, mixed types
From our picks that are no longer recruiting
Lymphoma, mixed b-cell types, relapsed with CD19 expression
  Testing Adoptive CART t-cell - Cellular Immunotherapy Following Cyclophosphamide
 Clicks as of 6/11/14: 37  Today: > (DONE)
Lymphoma, mixed indolent b-cell types: previously untreated indolent with low tumor burden
 Comparing GA101 (type II cd20 antibody) to Rituxan
 Clicks as of 4/27/14: 105  Today: >  (DONE)
b-cell lymphoma cd20 positive, relapsed or refractory
 Testing: Ublituximab (re-engineered cd20 antibody)  
 Study drug reports Clicks as of 4/27/14: 91 Today:  > 
b-cell lymphoma - DLBCL, indolent NHL, MCL, relapsed
 Testing: Ibrutinib WITH Rituxan-Bendamustine
  Clicks as of 4/27/14: 109 Today: > 
b-cell lymphoma, relapsed and refractory
 Testing: GS-9973 (oral syk inhibitor) WITH Idelalisib (b-cell receptor kinase inhibitor)
   Clicks as of 4/27/14: 86  Today: > 
b-cell lymphoma, low or high grade - including DLBCL, relapsed and refractory
 Testing: DCDT2980S OR DCDS4501A (antibody - drug conjugates) WITH Rituxan
 Clicks as of 4/27/14: 59  Today: > 
b-cell aggressive lymphoma,
relapsed and refractory, high-risk, intermediate grade (including transformed follicular)
 Testing: Adoptive T-cell therapy: Genetically Engineered Lymphocyte Therapy AFTER Transplant
Clicks as of 4/27/14: 36 Today: >  
b-cell NHL OR CLL cd-19 positive, high-risk, refractory to chemotherapy WITH at least 2 prior therapies
 Testing: Adoptive T-cell therapy:  Genetically Engineered Lymphocyte Therapy (CART)
Clicks as of 4/27/14: 256  Today: >  
b-cell NHL, indolent - FL, CLL, LPL, MZL - at least 2 prior therapies, not transformed
Testing: Idelalisib (GS01101 / CAL-101)
Clicks as of 1/20/13:  26  Today:  > 
b-cell NHL - DLBCL, indolent or aggressive cd20 positive lymphoma, no prior combination chemo
Testing: Ibrutinib WITH R-CHOP
Clicks as of 10/18/13: 48 Today: > 
b-cell, NHL / CLL, relapsed or refractory
Testing: DCDS4501A (cd79b antibody - drug conjugate) escalating doses
 Study drug reports Clicks as of 10/18/13: 100  Today: >
Lymphoma, mixed types:
DLBCL or transformed follicular with CD79 Mutation
Testing AEB071 - a Protein Kinase C Inhibitor
 Clicks as of 4/27/14: 67   Today: >  (Terminated)
Lymphoma, mixed B-cell types: MCL,
indolent NHL or DLBCL - relapsed and refractory
   Testing ABT-199 WITH Bendamustine-Rituximab
   Clicks as of 4/27/14: 159  Today: >  (DONE)
Lymphoma, mixed types:
B-cell Non-Hodgkins Lymphoma or CLL
   Testing Urelumab and Rituximab
Key eligibility: relapsed/refractory B-cell Malignancies; Follicular Lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)  patients must have at least 1 lesion that can be biopsied at screening and on treatment urelumab
Study drug reports : 22 Today: >  (DONE)

 


 
 Mantle Cell Lymphoma (MCL)

 See also lymphoma - mixed types, aggressive, and indolent

bullet
Locate trials for MCL
Open Phase III Controlled trials
 By treatment status: Untreated | Relapsed
bullet
Testing Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma  http://bit.ly/2ghv64V
bullet
MCL, relapsed or refractory
Testing KTE-C19 (CAR t19) in Relapsed/Refractory Mantle Cell Lymphoma Open 
 : 18 Today: > 
 
bullet
MCL, relapsed or refractory
Testing Ibrutinib (BTK Inhibitor) With Carfilzomib (Velcade-like) in Relapse/Refractory Mantle Cell Lymphoma Open 
 : 32 Today: > 

report http://1.usa.gov/1uAmwf0 
bullet
MCL previously untreated, over 60 years of age
Testing Bortezomib (Velcade) WITH Bendamustine-Rituxan Followed by Rituximab and Lenalidomide
 Study drug reports Clicks as of 10/19/13: 28  Today: > 

Return to Top
 
 

 

 

MCL
From our picks that are no longer recruiting
 
MCL, Newly Diagnosed
Testing Ibrutinib With Bendamustine and Rituxan
Locations:  Many sites in US and aboard but you must email sponsor for centers  Clicks as of 10/22/13: 45  Today: >  (DONE)
MCL relapsed
Testing Lenalidomide and Rituximab WITH or WITHOUT Idelalisib (CAL101)
 Locations:  Alliance trial - more sites should open soon
Clicks as of 5/9/2013: 28  Today:  >  (DONE)
MCL previously untreated,  OR did not achieve partial response after most recent treatment
Testing: Ibrutinib (btk-inhibitor / PCI-32765)
 Study drug reports  Clicks as of 1/20/13: 30 Today: > 
 
MCL relapsed, progressed after last Velcade Therapy
Testing: Ibrutinib (btk-inhibitor) Who Progress After Bortezomib (Velcade)
 Study drug reports Clicks as of 10/19/13:  25  Today:  > 
 



 Marginal Zone Cell Lymphoma (MZL) / MALT
 
  See also:  studies for mixed, aggressive, and indolent

bullet
Locate trials for MZL / MALT 
Open Phase III controlled trials
By treatment status: Untreated  | Relapsed
bullet
Testing clarithromycin-lenalidomide in patients with rrMALT lymphoma in phase-II “CLEO” trial https://clinicaltrials.gov/ct2/show/NCT03031483 
bullet
Marginal Zone, untreated, Ocular Adnexal
Testing First-line Doxycycline (antibiotic)  Open
Clicks as of 2/4/2106  NEW  Today >
bullet
Marginal zone and other indolent lymphoma
Testing Lenalidomide and Rituximab  Open
Clicks as of 2/4/2106  NEW  Today >
bullet
Marginal Zone and other indolent lymphoma,
Testing Rituximab and Zevalin Open
Clicks as of 2/4/2106  NEW  Today >
bullet
Marginal Zone and other indolent lymphoma,
Testing Rituximab Plus Lenalidomide versus Rituxan + placebo (RCT)  Open
Clicks as of 6/2/2016: New  Today >

 

Return to Top

 
 
 
MZL (MALT)
From our picks that are no longer recruiting
 

Marginal Zone lymphoma, relapsed and refractory    
 Testing Ibrutinib
Clicks as of 6/2/2016: 14  Today:  > 

Marginal Zone Lymphoma, refractory to last systemic therapy
Testing Ibrutinib
Clicks as of 6/2/2016: 356  Today:  >   (DONE)
MALT, previously treated or untreated
Testing Rituxan + Lenalidomide
Study drug reports   Clicks as of 6/2/2016 20  Today:  >  (DONE)

 

 


T-Cell Lymphoma

See also Lymphoma - mixed, aggressive, and indolent

bullet
Locate trials for T-cell lymphoma
Open Phase III Controlled trials
By treatment status:
bullet
T-cell lymphoma, mixed types, relapsed or refractory, PTCL only for expansion phase
Testing Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies - PTCL only for expansion phase Open
Clicks as of 6/2/2016: 29  Today >

Columbia University Medical Center Recruiting
New York, New York, United States, 10019
Contact: Ameet Narwal 212-326-5720
Principal Investigator: Jennifer E Amengual, MD
bullet
T-cell lymphoma, untreated, cd30 positive mature type
Comparing Brentuximab + CHP VS CHOP 
Study drug reports  Clicks as of 6/2/2016: 15  Today: > 
bullet
T-cell lymphoma, peripheral type, previously untreated
Comparing Romidepsin + CHOP VS CHOP 
Study drug reports   Clicks as of 6/2/2016: 16  Today: > 

Return to Top
 
 
 
T-cell Lymphoma
From our picks that are no longer recruiting
T-cell lymphoma, Mycosis Fungoides or Sézary Syndrome, Relapsed or Refractory, Stage IIB-IVB
Testing Lambrolizumab (PD1 antibody)  Open
Clicks as of 6/2/2016: 39  Today >  (Done)
T-cell lymphoma cutaneous (CTCL)  Early-Stage (IA-IIA), relapse after 1 or more treatments
Testing O6-Benzylguanine AND Topical Carmustine
Study drug reports  Clicks as of 4/29/14: 20 Today:  >  
T-cell lymphoma Peripheral type, relapsed or refractory
Testing: Alisertib (Aurora Kinase A Inhibitor - MLN8237
Study drug reports  Clicks as of 4/29/14: 28  Today:  > 
T-cell lymphoma PTCL and other aggressive types, previously untreated
Testing: SAHA (Vorinostat) WITH CHOP
 Study drug reports  Clicks as of 10/19/13: 30 Today: > 

T-cell lymphoma, peripheral type, previously untreated
Comparing Pralatrexate to Observation Following CHOP-based treatment 
 Clicks as of 6/2/2016: 11  Today: >  (Terminated)


 
 


Waldenstrom's

bullet
Locate WM trials
By treatment status:
bullet
Waldenström’s Macroglobulinemia -
 ClinicalTrials.gov All open studies
bullet
Locate Open Controlled (phase III) Studies

 

  

 


Other Indications, GVHD

GVHD (Graft versus Host Disease)
bullet
GVHD Phase 3 studies (controlled)
Locate Open Studies
bullet
Acute GVHD 
Locate Open Studies
bullet
Chronic GVHD 
Locate Open Studies
bullet
Steroid refractory GVHD 
Locate Open Studies
Studies of interest:
bullet
Graft versus Host Disease acute, steroid-refractory
Testing Brentuximab Vedotin for Steroid Refractory GvHD
Study drug reports   Clicks as of 10/19/13: 14 Today:  > 

Return to Top
 

  

Related Resources 

bullet
How long does it take to complete a typical study?    
How many completed studies advance practice or inform future studies? 

 Study Results for Lymphoma and CLL trials 
bullet
7 reasons to participate in clinical trials
bullet
Clinical Trials - News Medical: Helping cancer patients tackle geographic challenges to access clinical trials
bullet
News Medical:  Phase III study using ibrutinib in CLL patients completed  http://bit.ly/ZK8qZy
bullet
Dr. Sharman's CLL & Lymphoma Blog: New Study Available for CLL/NHL http://bit.ly/17BoHUi

Return to Top
 
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns, you should always consult your doctor. 
Copyright © 2004,  All Rights Reserved.